REM Sleep Suppression Induced by Selective Monoamine Oxidase Inhibitors

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1982 Jan 1

PMID 6817370

Citations 8

Authors

R M Cohen

D Pickar

D Garnett

S Lipper

J C Gillin

D L Murphy

Affiliations

Soon will be listed here.

Abstract

The effects of 4 weeks of treatment with the selective monoamine oxidase (MAO) inhibiting antidepressant clorgyline and pargyline on the sleep of affectively disordered patients were studied. Both inhibitors resulted in near total suppression of REM sleep, a decrease in total sleep time, and an increase in the percent of stage 2 sleep. Clorgyline also increased awake time and decreased total recording period and sleep latency. In general, changes were greater for clorgyline than for pargyline and were about 50% slower to return to baseline after clorgyline compared to pargyline discontinuation. The results were consistent with the hypothesis that selective inhibition of the MAO type A, as produced by clorgyline, is sufficient to induce marked sleep changes. MAO inhibitor-induced receptor changes are proposed to account for the time course of the REM suppression and the REM rebound observed upon withdrawal.

Citing Articles

The Defensive Activation Theory: REM Sleep as a Mechanism to Prevent Takeover of the Visual Cortex.

Eagleman D, Vaughn D Front Neurosci. 2021; 15:632853.

PMID: 34093109 PMC: 8176926. DOI: 10.3389/fnins.2021.632853.

Why does rem sleep occur? A wake-up hypothesis.

Klemm W Front Syst Neurosci. 2011; 5:73.

PMID: 21922003 PMC: 3166790. DOI: 10.3389/fnsys.2011.00073.

Associations of a regulatory polymorphism of monoamine oxidase-A gene promoter (MAOA-uVNTR) with symptoms of depression and sleep quality.

Brummett B, Krystal A, Siegler I, Kuhn C, Surwit R, Zuchner S Psychosom Med. 2007; 69(5):396-401.

PMID: 17585061 PMC: 2777888. DOI: 10.1097/PSY.0b013e31806d040b.

Mammalian sleep.

Staunton H Naturwissenschaften. 2005; 92(5):203-20.

PMID: 15843983 DOI: 10.1007/s00114-005-0618-0.

Correlation of changes in alpha 2-adrenoceptor number and locomotor responses to clonidine following clorgyline discontinuation.

Aulakh C, Cohen R, McLellan C, Murphy D Br J Pharmacol. 1983; 80(1):10-2.

PMID: 6317126 PMC: 2044958. DOI: 10.1111/j.1476-5381.1983.tb11042.x.

References

Spitzer R, Endicott J, Robins E . Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978; 35(6):773-82. DOI: 10.1001/archpsyc.1978.01770300115013. View

KARCZMAR A, LONGO V, de Carolis A . A pharmacological model of paradoxical sleep: the role of cholinergic and monoamine systems. Physiol Behav. 1970; 5(2):175-82. DOI: 10.1016/0031-9384(70)90061-2. View

Murphy D . Substrate-selective monoamine oxidases--inhibitor, tissue, species and functional differences. Biochem Pharmacol. 1978; 27(15):1889-93. DOI: 10.1016/0006-2952(78)90001-1. View

Kupfer D, Foster F, Reich L, Thompson S, Weiss B . EEG sleep changes as predictors in depression. Am J Psychiatry. 1976; 133(6):622-6. DOI: 10.1176/ajp.133.6.622. View

Peroutka S, Snyder S . Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science. 1980; 210(4465):88-90. DOI: 10.1126/science.6251550. View

Lipper S, Murphy D, Slater S, Buchsbaum M . Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berl). 1979; 62(2):123-8. DOI: 10.1007/BF00427124. View

Akindele M, Evans J, Oswald I . Mono-amine oxidase inhibitors, sleep and mood. Electroencephalogr Clin Neurophysiol. 1970; 29(1):47-56. DOI: 10.1016/0013-4694(70)90078-7. View

Hori T, Sugita Y, Koga E, Shirakawa S, Inoue K, Uchida S . Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard. Psychiatry Clin Neurosci. 2001; 55(3):305-10. DOI: 10.1046/j.1440-1819.2001.00810.x. View

Sitaram N, Wyatt R, Dawson S, Gillin J . REM sleep induction by physostigmine infusion during sleep. Science. 1976; 191(4233):1281-3. DOI: 10.1126/science.176724. View

10.

Hill S, Reyes R, Kupfer D . Imipramine and REM sleep: cholinergic mediation in animals. Psychopharmacology (Berl). 1980; 69(1):5-9. DOI: 10.1007/BF00426514. View

11.

Wyatt R, Chase T, Kupfer D, Scott J, Snyder F . Brain catecholamines and human sleep. Nature. 1971; 233(5314):63-5. DOI: 10.1038/233063a0. View

12.

Savage D, MENDELS J, Frazer A . Monoamine oxidase inhibitors and serotonin uptake inhibitors: differential effects on [3H]serotonin binding sites in rat brain. J Pharmacol Exp Ther. 1980; 212(2):259-63. View

13.

MENDELS J, Frazer A . The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain. Neuropharmacology. 1980; 19(5):447-54. DOI: 10.1016/0028-3908(80)90052-0. View

14.

Hawkins D, MENDELS J . Sleep disturbance in depressive syndromes. Am J Psychiatry. 1966; 123(6):682-90. DOI: 10.1176/ajp.123.6.682. View

15.

Kupfer D, Hanin I, Spiker D, Neil J, Coble P . EEG sleep and tricyclic plasma levels in primary depression. Commun Psychopharmacol. 1979; 3(2):73-80. View

16.

Siever L, Cohen R, Murphy D . Antidepressants and alpha 2-adrenergic autoreceptor desensitization. Am J Psychiatry. 1981; 138(5):681-2. DOI: 10.1176/ajp.138.5.681. View

17.

Murphy D, Lipper S, Slater S, Shiling D . Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man. Psychopharmacology (Berl). 1979; 62(2):129-32. DOI: 10.1007/BF00427125. View

18.

Cohen R, Campbell I, DAUPHIN M, Tallman J, Murphy D . Changes in alpha- and beta-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants. Neuropharmacology. 1982; 21(4):293-8. DOI: 10.1016/0028-3908(82)90091-0. View

19.

Gillin J, Wyatt R, Fram D, Snyder F . The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline. Psychopharmacology (Berl). 1978; 59(3):267-72. DOI: 10.1007/BF00426633. View

20.

Endicott J, Spitzer R . A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry. 1978; 35(7):837-44. DOI: 10.1001/archpsyc.1978.01770310043002. View